GLP-1 receptor agonists (GLP-1RAs), designed to mimic native GLP-1 while resisting degradation by dipeptidyl peptidase-4 (DPP-4), have become foundational in T2DM pharmacotherapy. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.